Characteristics of Hospitalized Elderly Patients with Severe Pneumonia Due to SARS-CoV-2, Vaccinated Against COVID-19.

Publication date: May 29, 2025

The introduction of COVID-19 vaccinations has significantly altered the course of the pandemic by markedly reducing the number of severe infection cases, hospitalizations, and deaths due to COVID-19. Elderly individuals constitute a particularly vulnerable group at risk of severe disease progression, which is often related to decreased immune system effectiveness and comorbidities. Severe infection outcomes in vaccinated individuals, though substantially rarer than in the unimmunized population, can still lead to death due to underlying health conditions. This analysis aims to describe the population of elderly individuals who, despite being vaccinated, died from interstitial pneumonia complicating SARS-CoV-2 infection. Data on the infection course and co-existing diseases were obtained from the database of the JcF3zef Struś Multispecialty City Hospital in Poznań, which was converted into a dedicated facility during the pandemic. The inclusion criteria for the analysis were being over 60 years of age on the day of hospital admission, confirmed pneumonia in radiological examination, COVID-19 infection confirmed by PCR test, and an adverse disease course resulting in death. Patients admitted to the hospital from 1 June 2021 to 31 December 2021 were analyzed. Out of all hospitalizations, only 18 individuals met the inclusion criteria. Given the small number of patients, the authors employed descriptive methods to illustrate the clinical states of the individual patients, presenting SARS-CoV-2 infection in the context of co-existing diseases that significantly affect prognosis. The qualitative analysis employed highlights the complex and multidimensional courses of severely ill COVID-19 patients more emphatically.

Open Access PDF

Concepts	Keywords
December	comorbidities
June	COVID-19
Pcr	COVID-19 vaccination
Pneumonia	hospitalization
Prognosis	interstitial pneumonia
	mortality
	multimorbidity
	older adults
	SARS-CoV-2

Semantics

Type	Source	Name
disease	MESH	Pneumonia
disease	MESH	COVID-19
disease	MESH	infection
disease	MESH	disease progression
pathway	REACTOME	Immune System
disease	MESH	death
disease	MESH	interstitial pneumonia
pathway	REACTOME	SARS-CoV-2 Infection
disease	IDO	facility
disease	IDO	disease course
drug	DRUGBANK	Methionine
disease	MESH	Infectious Diseases
drug	DRUGBANK	Coenzyme M
disease	MESH	cardiovascular disease
disease	MESH	obesity
disease	MESH	heart attacks
disease	MESH	strokes
disease	MESH	dyspnea
disease	MESH	cognitive impairment
disease	IDO	blood
drug	DRUGBANK	Creatinine
drug	DRUGBANK	Urea
disease	MESH	Comorbidity
disease	MESH	chronic illnesses
disease	IDO	immunosuppression
drug	DRUGBANK	Zoledronic acid
disease	MESH	hypertension
disease	MESH	kidney disease
disease	MESH	liver cirrhosis
disease	MESH	smell disorders
disease	MESH	functional status
drug	DRUGBANK	Oxygen
disease	MESH	Lymphopenia
disease	MESH	viral infection
disease	MESH	bacterial infections
disease	MESH	transient ischemic attack
disease	MESH	cerebrovascular disorders
disease	MESH	abnormalities
disease	MESH	frontotemporal dementia
disease	MESH	Parkinson’s disease
disease	MESH	cerebral palsy
disease	MESH	heart failure
disease	MESH	atherosclerosis
disease	MESH	diabetes mellitus
disease	IDO	history
disease	MESH	ischemic stroke
disease	MESH	dilated cardiomyopathy
pathway	KEGG	Dilated cardiomyopathy
disease	MESH	anemia
disease	MESH	vitamin B12 deficiency
disease	MESH	ependymoma
disease	MESH	hemiparesis
disease	MESH	morbid obesity
disease	MESH	persistent atrial fibrillation
disease	MESH	nutritional deficiencies
disease	MESH	dementia
disease	MESH	syndromes
disease	MESH	Cardiac Diseases
disease	MESH	stenosis
disease	MESH	atrioventricular block
disease	MESH	heart block
disease	MESH	fatal outcomes
disease	MESH	ST segment elevation myocardial infarction
disease	MESH	cardiac arrest
disease	MESH	non ST elevation myocardial infarction
disease	MESH	ventricular fibrillation
disease	MESH	ischemic heart disease
disease	MESH	mitral stenosis
disease	MESH	tricuspid regurgitation
disease	MESH	complications
disease	MESH	hyperthyroidism
drug	DRUGBANK	Trestolone
disease	MESH	gout
drug	DRUGBANK	Allopurinol
disease	MESH	Rheumatic diseases
disease	MESH	Neurological disorders
disease	MESH	musculoskeletal diseases
disease	MESH	Respiratory diseases
disease	MESH	vascular diseases
disease	MESH	fibrosis
disease	MESH	Respiratory failure
disease	MESH	consciousness disorders
drug	DRUGBANK	Tocilizumab
drug	DRUGBANK	Baricitinib
disease	MESH	sudden cardiac arrest
disease	MESH	acute coronary syndrome
disease	MESH	Bladder tumor
disease	MESH	sepsis
disease	MESH	clostridium difficile infection
disease	MESH	diverticulitis
disease	MESH	End stage renal disease
disease	MESH	Hearing loss
disease	MESH	hemorrhages
disease	MESH	coronary artery disease
disease	MESH	hypercholesterolemia
disease	MESH	hypertrophy
disease	MESH	pulmonary fibrosis
disease	MESH	Chronic kidney disease
disease	MESH	Hypothyroidism
disease	MESH	arrhythmia
drug	DRUGBANK	Benzodiazepine
disease	MESH	etiology
disease	MESH	infarction
disease	MESH	dysarthria
disease	MESH	umbilical hernia
disease	MESH	rheumatoid arthritis
pathway	KEGG	Rheumatoid arthritis
disease	MESH	urinary tract infection
disease	MESH	venous insufficiency
disease	MESH	vitamin deficiency
disease	MESH	acute pancreatitis
disease	MESH	pleural empyema
disease	MESH	kidney failure
disease	MESH	esophageal varices
disease	MESH	hepatic encephalopathy
disease	MESH	hyponatremia
disease	MESH	hypokalemia
disease	MESH	circulatory failure
disease	MESH	hiatal hernia
disease	MESH	COPD
disease	MESH	deep vein thrombosis
disease	MESH	peripheral artery disease
disease	MESH	ischemia
disease	MESH	varicose vein
drug	DRUGBANK	Methimazole
disease	MESH	pressure ulcer
disease	MESH	breakthrough infections
disease	IDO	host
disease	MESH	frailty
disease	IDO	protein
disease	MESH	autoimmune diseases
disease	MESH	emergency

Original Article

(Visited 2 times, 1 visits today)